The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
plasmaMATCH is a multi-centre phase IIa umbrella trial platform consisting of a ctDNA
screening component and a therapeutic component. plasmaMATCH aims to assess whether ctDNA
screening can be used to detect patient subgroups who will be sensitive to targeted
therapies, and will also assess the safety and activity of the targeted treatments.